
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):
November 9, 2023

CLEARPOINT NEURO, INC.

(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction
of incorporation)

001-34822
(Commission
File Number)

58-2394628
(I.R.S. Employer
Identification Number)

120 S. Sierra Ave., Suite 100
Solana Beach, CA 92075
(Address of principal executive offices, zip code)

(888) 287-9109
(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, \$0.01 par value per share	CLPT	Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging Growth Company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 2.02. Results of Operations and Financial Condition.

On November 9, 2023, ClearPoint Neuro, Inc. (the “Company”) issued a press release announcing its financial performance for the third fiscal quarter ended September 30, 2023. A copy of the press release is furnished herewith as Exhibit 99.1.

The information in Item 2.02 of this Form 8-K, as well as Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 7.01. Regulation FD Disclosure.

On November 9, 2023, the Company posted an updated investor presentation to its website at <http://ir.stockpr.com/clearpointneuro/investor-presentations>. A copy of the investor presentation is being furnished herewith as Exhibit 99.2. The Company may use the investor presentation from time to time in conversations with analysts, investors and others.

The information in Item 7.01 of this Form 8-K, as well as Exhibit 99.2 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

The following exhibit is furnished herewith:

Exhibit 99.1	Press Release dated November 9, 2023
Exhibit 99.2	Investor Presentation dated November 9, 2023
Exhibit 104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: November 9, 2023

CLEARPOINT NEURO, INC.

By: /s/ Danilo D'Alessandro
Danilo D'Alessandro
Chief Financial Officer



ClearPoint Neuro Reports Third Quarter 2023 Results Biologics & Drug Delivery Growing 55%; Q3 Operational Cash Burn of \$1.8M

SOLANA BEACH, CA, November 9, 2023 – ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced financial results for its third quarter ended September 30, 2023.

Third Quarter Highlights

- Reported quarterly revenue of \$5.8 million, a 12% year-over-year increase;
- Increased biologics and drug delivery revenue to \$3.5 million, a 55% year-over-year increase;
- Operational cash burn of \$1.8 million, the lowest quarterly burn since 2020;
- Entered into new strategic biologics and drug delivery agreements, including additional milestone-based agreement;
- Submitted three new stereotactic products to the FDA for 510(k) clearance;
- Submitted one 510(k) clearance to the FDA for updated software that allows the ClearPoint Navigation Software to incorporate the Maestro Brain Model;
- Completed the transition to the new manufacturing facility in Carlsbad, California, which is now producing and shipping sellable product to customers;
- Cash and cash equivalents totaled \$24.3 million as of September 30, 2023.

Business Outlook

- With additional focus on near-term investments that drive profitable growth, the company now forecasts 2023 total revenue between \$23.0 and \$25.0 million representing growth between 11% and 18% for the year.

“The third quarter was productive for the team as we continued to grow double digits while meaningfully reducing our operational cash burn,” commented Joe Burnett, President and CEO at ClearPoint Neuro. “We believe that our long-term vision and strategy remain unchanged, however we are committed to focusing our near-term activities on profitable growth as our third quarter demonstrated. Despite reducing our quarterly operational cash burn to the lowest level since 2020, we were still able to execute multiple new strategic biologics and drug delivery agreements, expand our PRISM laser therapy system to new centers, execute multiple new product FDA submissions, and complete the transition of manufacturing to our new facility in Carlsbad, California ahead of schedule, improving gross margin and eliminating redundant costs heading into 2024.”

Financial Results – Quarter Ended September 30, 2023

Total revenue was \$5.8 million for the three months ended September 30, 2023, and \$5.1 million for the three months ended September 30, 2022, which represents an increase of \$0.6 million, or 12%.

Biologics and drug delivery revenue, which includes sales of disposable products and services related to customer-sponsored pre-clinical and clinical trials utilizing our products, increased 55% to \$3.5 million for the three months ended September 30, 2023, from \$2.2 million for the same period in 2022.

Functional neurosurgery navigation and therapy revenue, decreased 21% to \$1.9 million for the three months ended September 30, 2023, from \$2.4 million for the same period in 2022. The decrease is driven primarily by lower service revenue of \$0.3 million as a result of pausing a co-development program with one of our Brain Computer Interface partners.

Capital equipment and software revenue, consisting of sales of ClearPoint reusable hardware and software, and of related services, decreased 26% to \$0.4 million for the three months ended September 30, 2023, from \$0.5 million for the same period in 2022.

Gross margin for the three months ended September 30, 2023, was 57%, as compared to a gross margin of 71% for the three months ended September 30, 2022. The decrease in gross margin was primarily due to an increase in biologics and drug delivery preclinical services, which, to date, have had a lower margin than prior year as we launch new services and increase our presence in this space. Increased costs related to the transition to the new manufacturing facility have also contributed to the decrease in gross margin compared to prior year.

Operating expenses for the third quarter of 2023 were \$8.2 million, compared to \$7.5 million for the third quarter of 2022. The increase was mainly driven by the increase in headcount across the organization and share-based compensation as well as an increase in the allowance for credit losses, offset slightly by lower research and development costs.

At September 30, 2023, the Company had cash and cash equivalents and short-term investments totaling \$24.3 million as compared to \$37.5 million at December 31, 2022, with the decrease resulting primarily from the use of cash in operating activities of \$12.6 million.

Teleconference Information

Investors and analysts are invited to listen to a live broadcast review of the Company's 2023 third quarter on Thursday, November 9, 2023 at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) which may be accessed online here: <https://event.choruscall.com/mediaframe/webcast.html?webcastid=dhaAzhXA>. Investors and analysts who would like to participate in the conference call via telephone may do so at (800) 715-9871, or at (646) 307-1963 if calling from outside the U.S. or Canada.

For those who cannot access the live broadcast, a replay will be available shortly after the completion of the call until December 9, 2023, by calling (877) 660-6853, or (201) 612-7415 if calling from outside the U.S. or Canada, and then entering conference I.D. number 413671. An online archive of the broadcast will be available on the Company's Investor website at <https://ir.clearpointneuro.com/>.

About ClearPoint Neuro

ClearPoint Neuro's mission is to improve and restore quality of life to patients and their families by enabling therapies for the most complex neurological disorders with pinpoint accuracy. Applications of the Company's current product portfolio include deep brain stimulation, laser ablation, biopsy, and delivery of drugs, biologics, and gene therapy to the brain. The ClearPoint Neuro Navigation System has FDA clearance, is CE-marked, and is installed in over 65 sites in North America, Europe, and South America. ClearPoint Neuro is partnered with more than 50 pharmaceutical/biotech companies, academic centers, and contract research organizations providing solutions for direct CNS delivery of therapeutics in pre-clinical studies and clinical trials worldwide. To date, more than 6,000 procedures have been performed and supported by the Company's field-based clinical specialist team, which offers support and services to our customers and partners worldwide. For more information, please visit www.clearpointneuro.com.

Forward-Looking Statements

Statements in this press release and in the teleconference referenced above concerning the Company's plans, growth and strategies may include forward-looking statements within the context of the federal securities laws. Statements regarding the Company's future events, developments and future performance, the size of total addressable markets or the market opportunity for the Company's products and services, as well as management's expectations, beliefs, plans, estimates or projections relating to the future, are forward-looking statements within the meaning of these laws. Uncertainties and risks may cause the Company's actual results to differ materially from those expressed in or implied by forward-looking statements. Particular uncertainties and risks include those relating to: the impact of macroeconomic and inflationary conditions, global instability, supply chain disruptions, and labor shortages; future revenue from sales of the Company's hardware and software products and biologics and drug delivery consulting services; the Company's ability to market, commercialize and achieve broader market acceptance for the Company's hardware and software products and service offerings, including our biologics and drug delivery partners' use of our products and services in their delivery of therapies; our biologics and drug delivery partners' ability to fund their business activities, conduct further research and development, and achieve success in their studies and clinical trials; and risks inherent in the research and development and regulatory approval of new products. More detailed information on these and additional factors that could affect the Company's actual results are described in the "Risk Factors" section of the Company's Annual Report on Form 10-K for the year ended December 31, 2022, and the Company's Quarterly Report on Form 10-Q for the three months ended June 30, 2023, both of which have been filed with the Securities and Exchange Commission, and the Company's Quarterly Report on Form 10-Q for the three months ended September 30, 2023, which the Company intends to file with the Securities and Exchange Commission on or before November 14, 2023.

Contact:

Danilo D'Alessandro, Chief Financial Officer

(949) 900-6833

info@clearpointneuro.com

Caroline Corner, Investor Relations

ir@clearpointneuro.com

CLEARPOINT NEURO, INC.
Consolidated Statements of Operations
(Unaudited)
(Dollars in thousands, except for share and per share data)

	For The Three Months Ended September 30,	
	2023	2022
Revenue:		
Product revenue	\$ 2,410	\$ 3,130
Service and other revenue	3,352	2,016
Total revenue	5,762	5,146
Cost of revenue	2,489	1,467
Gross profit	3,273	3,679
Research and development costs	2,429	2,654
Sales and marketing expenses	2,841	2,422
General and administrative expenses	2,900	2,398
Operating loss	(4,897)	(3,795)
Other expense:		
Other expense, net	(12)	(25)
Interest income, net	100	32
Net loss	\$ (4,809)	\$ (3,788)
Net loss per share attributable to common stockholders:		
Basic and diluted	\$ (0.20)	\$ (0.15)
Weighted average shares used in computing net loss per share:		
Basic and diluted	24,630,181	24,497,636

	For The Nine Months Ended September 30,	
	2023	2022
Revenue:		
Product revenue	\$ 7,377	\$ 9,750
Service and other revenue	9,768	5,627
Total revenue	17,145	15,377
Cost of revenue	7,544	5,212
Gross profit	9,601	10,165
Research and development costs	9,057	7,967
Sales and marketing expenses	9,248	6,826
General and administrative expenses	9,036	7,235
Operating loss	(17,740)	(11,863)
Other expense:		
Other expense, net	(25)	(22)
Interest income (expense), net	295	(165)
Net loss	\$ (17,470)	\$ (12,050)
Net loss per share attributable to common stockholders:		
Basic and diluted	\$ (0.71)	\$ (0.50)
Weighted average shares used in computing net loss per share:		
Basic and diluted	24,599,191	24,058,205

CLEARPOINT NEURO, INC.
Consolidated Balance Sheets
(Dollars in thousands, except for share and per share data)

	September 30, 2023 (Unaudited)	December 31, 2022
ASSETS		
Current assets:		
Cash and cash equivalents	\$ 24,342	\$ 27,615
Short-term investments, at amortized cost	—	9,874
Accounts receivable, net	2,424	2,665
Inventory, net	8,987	9,303
Prepaid expenses and other current assets	1,557	1,723
Total current assets	37,310	51,180
Property and equipment, net	1,355	806
Operating lease, right-of-use assets	3,689	1,895
Software license inventory	405	450
Licensing rights	969	1,028
Other assets	109	131
Total assets	\$ 43,837	\$ 55,490
LIABILITIES AND STOCKHOLDERS' EQUITY		
Current liabilities:		
Accounts payable	\$ 789	\$ 272
Accrued compensation	2,288	2,824
Other accrued liabilities	953	2,065
Operating lease liabilities, current portion	384	561
Deferred product and service revenue, current portion	1,175	1,066
Total current liabilities	5,589	6,788
Operating lease liabilities, net of current portion	3,695	1,532
Deferred product and service revenue, net of current portion	524	390
2020 senior secured convertible note payable, net	9,935	9,893
Total liabilities	19,743	18,603
Commitments and contingencies		
Stockholders' equity:		
Preferred stock, \$0.01 par value; 25,000,000 shares authorized; none issued and outstanding at September 30, 2023 and December 31, 2022	—	—
Common stock, \$0.01 par value; 90,000,000 shares authorized at September 30, 2023 and 200,000,000 shares authorized at December 31, 2022; 24,625,670 shares issued and outstanding at September 30, 2023; and 24,578,983 issued and outstanding at December 31, 2022	246	246
Additional paid-in capital	191,685	187,008
Accumulated deficit	(167,837)	(150,367)
Total stockholders' equity	24,094	36,887
Total liabilities and stockholders' equity	\$ 43,837	\$ 55,490

CLEARPOINT NEURO, INC.
Consolidated Statements of Cash Flows
(Unaudited)
(Dollars in thousands)

	For The Nine Months Ended September 30,	
	2023	2022
Cash flows from operating activities:		
Net loss	\$ (17,470)	\$ (12,050)
Adjustments to reconcile net loss to net cash flows from operating activities:		
Allowance for credit losses (recoveries)	903	(92)
Depreciation and amortization	443	224
Share-based compensation	4,536	2,954
Amortization of debt issuance costs and original issue discounts	42	41
Amortization of lease right-of-use, net of accretion in lease liabilities	590	400
Accretion of discounts on short-term investments	(126)	(159)
Increase (decrease) in cash resulting from changes in:		
Accounts receivable	(662)	(982)
Inventory, net	263	(3,318)
Prepaid expenses and other current assets	241	(1,150)
Other assets	22	31
Accounts payable and accrued expenses	(1,023)	1,255
Lease liabilities	(553)	(400)
Deferred revenue	243	144
Net cash flows from operating activities	(12,551)	(13,102)
Cash flows from investing activities:		
Purchases of property and equipment	(696)	(214)
Acquisition of licensing rights	(167)	(678)
Purchase of short-term investments	—	(21,590)
Proceeds from maturities of short-term investments	10,000	—
Net cash flows from investing activities	9,137	(22,482)
Cash flows from financing activities:		
Proceeds from stock option and warrant exercises	—	263
Payments for taxes related to net share settlement of equity awards	(173)	(336)
Proceeds from issuance of common stock under employee stock purchase plan	314	260
Net cash flows from financing activities	141	187
Net change in cash and cash equivalents	(3,273)	(35,397)
Cash and cash equivalents, beginning of period	27,615	54,109
Cash and cash equivalents, end of period	<u>\$ 24,342</u>	<u>\$ 18,712</u>
SUPPLEMENTAL CASH FLOW INFORMATION		
Cash paid for:		
Income taxes	\$ —	\$ —
Interest	<u>\$ 554</u>	<u>\$ 351</u>



CLEARPOINT®
NEURO

WHEN YOUR PATH IS UNCLEAR,
WE POINT THE WAY.™



Nasdaq: CLPT

November 2023



Statements herein concerning the Company's plans, growth and strategies may include forward-looking statements within the context of the federal securities laws. Statements regarding the Company's future events, developments and future performance, the size of total addressable markets or the market opportunity for the Company's products and services, as well as management's expectations, beliefs, plans, estimates or projections relating to the future, are forward-looking statements within the meaning of these laws. Uncertainties and risks may cause the Company's actual results to differ materially from those expressed in or implied by forward-looking statements. Particular uncertainties and risks include those relating to: the impact of macroeconomic and inflationary conditions, global instability, supply chain disruptions, and labor shortages; future revenue from sales of the Company's hardware and software products and biologics and drug delivery consulting services; the Company's ability to market, commercialize and achieve broader market acceptance for the Company's hardware and software products and service offerings, including our biologics and drug delivery partners' use of our products and services in their delivery of therapies; our biologics and drug delivery partners' ability to fund their business activities, conduct further research and development, and achieve success in their studies and clinical trials; and risks inherent in the research and development and regulatory approval of new products. More detailed information on these and additional factors that could affect the Company's actual results are described in the "Risk Factors" section of the Company's Annual Report on Form 10-K for the year ended December 31, 2022, and the Company's Quarterly Report on Form 10-Q for the three months ended June 30, 2023, both of which have been filed with the Securities and Exchange Commission, and the Company's Quarterly Report on Form 10-Q for the three months ended September 30, 2023, which the Company intends to file with the Securities and Exchange Commission on or before November 14, 2023.

ClearPoint Neuro: Two Opportunities, One Platform



←→
A Common Installed Base Platform and
Clinical Specialist Support team
35 Active Indications totaling more than
1 million patients diagnosed annually
A \$12B+ Potential Total Addressable Market

1 A Biologics & Drug Delivery Enabling Company with:

- A unique portfolio of Navigation Tools, Infusion Cannulas, Pre-Clinical and Clinical Services
- More than 50 active pharma/biotech, academic and contract research organization partners

2 A Neuro Navigation and Device Company with:

- A growing portfolio of Navigation, Therapy and Access Devices supporting DBS, Laser Ablation, Biopsy and Brain Computer Interface implantation
- An expanding global installed base of more than 65 centers

ClearPoint Neuro: A Proven Platform

Key Products: FDA CE Marked Platforms

HEADQUARTERS

Solana Beach, CA

MANUFACTURING

Carlsbad, CA

EUROPEAN HEADQUARTERS

London, UK

2023 EXPECTED REVENUE

\$23-\$25m^(A)

CASH & CASH EQUIVALENTS

\$24.3m^(B)

PATENTS ISSUED

100+^(C)

GROSS MARGIN

60%^(B,D)

EMPLOYEES

100+



(A) Estimated and subject to revision

(B) Unaudited as of, and for the quarter ended, September 30, 2023

(C) Including owned and licensed patents

(D) For the Trailing Twelve Months (TTM)

Limitations of Traditional Stereotactic Neurosurgery

Lack of Real-Time Image Guidance

PRIMARY CHALLENGE

For minimally invasive procedures to be successful, the surgeon needs imaging to see into the head

MRI is the best imaging tool for the brain

Large, metallic frames are not MRI compatible



Big Iron companies like Siemens and Philips are innovating to make interoperative MRI scanners more accessible



One Platform, Multiple Indications

The ClearPoint® Neuro Navigation System


Anon2014-09-26_07-00
26-Sep-14 11:00:10 AM
WL: 9.001:4.028

Anon2014-09-26_07-00
26-Sep-14 11:00:10 AM
WL: 9.001:4.028

Neuromodulation
Parkinson's Disease, OCD,
Epilepsy, Dystonia




Drug Delivery
Approved Rare Genetic Disorders +
30 Indications in Clinical Trials





Biopsy
Glioblastoma, Diffuse Intrinsic
Pontine Glioma, etc.

Laser Therapy
Epilepsy, Tumors, Parkinson's,
Essential Tremor




SmartFrame® XG



SmartFrame XG Trajectory Tower
with ClearPoint 2.1 Software

SmartFrame Array®




SmartFrame Array Tower
with "virtual array" Software and next generation robotic
system with increased automation and enabling software*

ClearPoint plans to translate more than 10 years of experience
and over 6,000 cases performed in the complex MRI suite into
unique and competitive products for the Operating Room

Our Platform

The ClearPoint 'Maestro' Brain Model* Licensed and Jointly Developed with Philips

1. Shape Constrained, triangular mesh model enables point-based correspondence across multiple subjects.
2. Fast and capable of peri-procedural imaging without CPU acceleration.
3. Import DICOM volume bitmasks into ClearPoint software today to assist Neurosurgeons with Targeting and Pharma partners with volume dosing calculations for drug delivery trials.
4. Basis for future navigation tools, for both the MRI suite and OR, across Biologics & Drug Delivery, DBS Navigation, Brain Computer Interface, Laser Ablation and more.



Broad and Growing User Base of Leading Neurosurgery Centers

65+ Centers in the US, EU, Brazil and Canada... and Growing Globally

UC San Francisco
Stanford University
Lucile Packard Children's Hospital
Benioff Children's Hospital
San Francisco VA
USC Keck Hospital
UC San Diego
Mayo Clinic in Arizona
University of Colorado
University of Utah
Cook Children's Hospital
Texas Children's Hospital
MD Anderson Cancer Center
Houston Methodist Hospital
Univ. Kansas Medical Center
Dallas Presbyterian Hospital
Cincinnati Jewish Hospital
Children's National Hospital
Banner Health Tucson
Ohio State University
University of Oklahoma Medical Center
Methodist Hospital San Antonio
Barnes-Jewish Hospital
Froedtert Hospital
Cleveland Clinic
UT Southwestern Medical Center

University of Wisconsin
University of Michigan
University of Minnesota
Carilion Clinic
Northwestern Central DuPage
Nationwide Children's
Le Bonheur
INOVA Fairfax
Cincinnati Children's Hospital
Riverside Methodist Hospital
Henry Ford Health

Charles River Labs – Laval
Charles River Labs – Mattawan
Children's Mercy Hospital
CHOA Scottish Rite
UPMC
Hos. Univ. of Pennsylvania
Duke University
JFK University Medical Center
University of Alabama at Birmingham
Children's Hospital of Alabama
Mayo Clinic in Florida

Rigshospitalet (Copenhagen, Denmark)
Mazowiecki Szpital Bródnowski (Warsaw, Poland)
Hôpital Fondation Rothschild (Paris, France)
Skånes Universitetssjukhus Lund (Lund, Sweden)
Sahlgrenska Universitetssjukhuset (Gothenburg, Sweden)
University Hospital of Wales (United Kingdom)
Universitätsklinikum Düsseldorf (Düsseldorf, Germany)
Universitätsklinikum Freiburg (Freiburg, Germany)
Policlinico Umberto I (Rome, Italy)
Hospital Israelita Albert Einstein (São Paulo, Brazil)

Emory University
Mt. Sinai West
Yale University
Weill Cornell
Johns Hopkins University
Boston Children's Hospital
Massachusetts General Hospital
Brigham & Women's
National Institutes of Health
Memorial Sloan-Kettering
Dartmouth-Hitchcock
Beth Israel Deaconess
Children's Hospital of Philadelphia
Hackensack Univ. Med. Center
University of Virginia
Tampa General Hospital
Baptist Medical Center Jacksonville

100+
Centers
Expected
by 2025

A Therapy-Enabling Platform

The ClearPoint Platform has been used in over 6,000 procedures to...

Deliver Biologics & Drugs*



...with 50+ industry and academic partners

Implant Neuro Stimulation Leads




Administer Laser Therapy



ClearPoint Navigation is Compatible with all Major Diagnostic and Intraoperative MRI Scanners



Growth in Product and Service Revenue



~\$12B+ Opportunity: Empowering Multiple Treatment Options for 35 Indications*

Indication	Patient Population	Annual Incidence	Pillar 1: Drug/Cell Delivery	Pillar 2: DBS & BCI	Pillar 3: Laser Therapy	Incremental Revenue from Annual Incidence
Parkinson's Disease	1,000,000 ¹	60,000 ¹	○ ○	●	●	\$270 M - \$1.35 B
Drug Resistant Epilepsy	1,000,000 ²	11,000 ³	○ ○	●	●	\$49.5 M - \$198 M
Refractory Essential Tremor	3,500,000 ⁴	60,000 ⁵		●	○	\$180 M - \$1.08 B
Brain Tumors (n=3) ⁶	35,000 ^{7,8}	13,300 ^{7,8}	○ ○		●	\$33.3 M - \$300 M
Severe Obsessive-Compulsive Disorder	500,000 ^{9,10}	10,000 ^{9,10}		●		\$45 M - \$75 M
Dystonia	250,000 ¹¹	8,000 ¹²		●		\$36 M - \$60 M
Rare Genetic/Lysosomal (n=7) ¹³	36,500 ¹⁴⁻¹⁸	3,000 ^{14,19,20}	○ ●			\$13.5 M - \$67.5 M
Paralysis / Spinal Cord (n=15) ^{21,22}	331,000 ²²⁻²⁴	17,900 ²³	○ ○	○		\$80.6 M - \$403 M
Huntington's Disease	30,000 ²⁵	4,000 ²⁵	○ ○	○		\$18 M - \$90 M
Alzheimer's Disease	6,000,000 ²⁶	500,000 ²⁶	○ ○	○		\$1.5 B - \$11.3 B
Severe Major Depressive Disorder	1,000,000 ¹⁰	20,000 ^{10,27}		○		\$90 M - \$150 M
Stroke Rehabilitation	2,000,000 ²⁸	610,000 ²⁸		○		\$1.83 B - \$5.49 B
Frontotemporal Dementia	60,000 ²⁹	12,000 ²⁹	○			\$54 M - \$270 M
						\$4.2 B - \$20.8 B

ESTIMATED LAUNCH SEQUENCE

- Commercial U.S or EU ClearPoint procedures today
- Active clinical trial
- Pre-clinical study/testing






















ClearPoint Neuro Navigation Capital, Robotics & Disposables
 Cannulas, Pumps | MER Probes | Laser Cath., Biopsy
 Access Technologies, Clinical Services, Digital Health

*Citations & footnotes on next slide

Citations & Footnotes

1. "Parkinson's Disease Statistics," Parkinson's News Today, <https://parkinsonsnewstoday.com/parkinsons-disease-statistics/#:~:text=An%20estimated%20seven%20to%2010,who%20are%2080%20and%20older>
2. Neuron Therapeutics. (2021 November 4). *Neuron Therapeutics Receives IND Clearance to Initiate Phase 1/2 Clinical Trial of Neural Cell Therapy NRTX-1001 in Chronic Focal Epilepsy Patients* [Press release] https://www.neurontherapeutics.com/wp-content/uploads/2021/11/2021_11_01_-INDClearance_FINALVersion.pdf
3. Asadi-Pooya AA, Stewart GR, Abrams DJ, Sharan A. Prevalence and Incidence of Drug-Resistant Mesial Temporal Lobe Epilepsy in the United States. *World Neurosurg.* 2017;99:662-666.
4. Zesiewicz TA, Chari A, Jahan I, Miller AM, Sullivan KL. Overview of essential tremor. *Neuropsychiatr Dis Treat.* 2010;6:401-408. Published 2010 Sep 7.
5. Diaz NL, Louis ED. Survey of medication usage patterns among essential tremor patients: movement disorder specialists vs. general neurologists. *Parkinsonism Relat Disord.* 2010;16(9):604-607.
6. Includes: Glioblastoma, Diffuse Intrinsic Pontine Glioma and deep small eloquent brain tumors.
7. "Glioblastoma Multiforme," American Association of Neurological Surgeons, <https://www.aans.org/en/Patients/Neurosurgical-Conditions-and-Treatments/Glioblastoma-Multiforme>
8. "About DIPG/DMG," DIPG/DMG Registry, <https://dipgregistry.org/patients-families/about-dipg-dmg/>
9. Medtronic Clinical Summary – Reclaim DBS for Chronic Extreme OCD M947128A001.
10. Mantovani A, Lisanby SH. Brain stimulation in the treatment of anxiety disorders. In: Simpson HB, Neria Y, Lewis-Fernández R, Schneier F, eds. *Anxiety Disorders: Theory, Research and Clinical Perspectives*. Cambridge: Cambridge University Press; 2010:323-335.
11. <https://www.aans.org/en/Patients/Neurosurgical-Conditions-and-Treatments/Dystonia>
12. Medtronic DBS™ Therapy for Dystonia - Clinical Summary 2015.
13. Includes: AADC deficiency, Friedreich's ataxia, Angelman syndrome, multiple system atrophy, metachromatic leukodystrophy, and spinocerebellar ataxia type 3.
14. "Multiple System Atrophy," Medscape, <https://emedicine.medscape.com/article/1154583-overview#a6>
15. PTC Therapeutics November 30, 2021 Corporate Presentation, <https://ir.ptcbio.com/static-files/0fd5d54f-55b8-416b-8006-4eb4c0d82f45>
16. "Spinocerebellar ataxia type 3," Orphanet, https://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=EN&Expert=98757
17. Lysogene Corporate Presentation at 38th Annual J.P. Morgan Healthcare Conference on Jan 13, 2020, http://www.lysogene.com/wp-content/uploads/2020/01/jpm-2020-corporate-presentation_final.pdf
18. "Metachromatic Leukodystrophy," National Organization of Rare Disorders, <https://rarediseases.org/rare-diseases/metachromatic-leukodystrophy/>
19. "Aromatic L'Amino Acid Decarboxylase Deficiency," National Organization for Rare Disorders, <https://rarediseases.org/rare-diseases/aromatic-l-amino-acid-decarboxylase-deficiency/>
20. Puckett Y, Mallorga-Hernández A, Montañó AM. Epidemiology of mucopolysaccharidoses (MPS) in United States: challenges and opportunities. *Orphanet J Rare Dis.* 2021;16(1):241. Published 2021 May 29.
21. Includes: stroke, spinal cord injury, multiple sclerosis, cerebral palsy, other (traumatic brain injury, complications from surgery, amyotrophic lateral sclerosis, neurofibromatosis, Chiari malformation, syringomyelia, postpolio syndrome, spinal muscular atrophy, Friedreich's ataxia, transverse myelitis, and spina bifida).
22. Armour BS, Courtney-Long EA, Fox MH, Fredine H, Cahill A. Prevalence and Causes of Paralysis-United States, 2013. *Am J Public Health.* 2016;106(10):1855-1857.
23. Wyndaele M, Wyndaele JJ. Incidence, prevalence and epidemiology of spinal cord injury: what learns a worldwide literature survey?. *Spinal Cord.* 2006;44(9):523-529.
24. National Spinal Cord Injury Statistical Center (NSCISC): 2020 Annual Report and 2021 Facts and Figures. <https://www.nscisc.uab.edu/>
25. "Huntington's Disease," *Mov Disord.* 2019 Jun; 34(6): 858–865.
26. "Alzheimer's Disease: Facts & Figures," Brightfocus Foundation, <https://www.brightfocus.org/alzheimers/article/alzheimers-disease-facts-figures>
27. Goodman WK, Alterman RL. Deep brain stimulation for intractable psychiatric disorders. *Annu Rev Med.* 2012;63:511-524.
28. "Stroke Facts," Center for Disease Control and Prevention, <https://www.cdc.gov/stroke/facts.htm>
29. Onyike CU, Diehl-Schmid J. The epidemiology of frontotemporal dementia. *Int Rev Psychiatry.* 2013;25(2):130-137.

ClearPoint Neuro is Dedicated to Innovation in the Neuro Space

	First Use in 2022	Active Development Programs*
Functional Navigation & Therapy	 <p>ClearPoint Neuro Navigation Software v. 2.1</p>	 <p>ClearPoint Maestro® Brain Model</p>
	 <p>ClearPoint Prism™ Neuro Laser Therapy System</p>	 <p>Brain Computer Interface Navigation</p>  <p>Maestro® Sub-Nuclei Brain Model</p>  <p>Revolution™ Robotic-Assisted Navigation Closed Loop Robotic-Assisted Navigation</p>  <p>Maestro® Area of Activation Application</p>  <p>CT Based Navigation w/ Maestro® Brain Model</p>  <p>Z-Axis Robotics</p>
Biologics & Drug Delivery, Access Technologies	 <p>Expanded Pre-Clinical Development Services for Pharma</p>	 <p>ClearPoint Maestro® Infusion Modeling App*</p>
	 <p>ClearPoint Orchestra™ Pre-Clinical Head Fixation Frame</p>  <p>Operating Room Drill</p>	 <p>ClearPoint Orchestra™ Head Fixation Frame</p>  <p>ClearPoint Maestro® Infusion Targeting App</p>  <p>Spinal Infusion Catheter</p>  <p>MRI Suite Safe Drill</p>  <p>Flexible, Chronic Drug Delivery Infusion Catheters</p>  <p>Radially Branching Cell Therapy Devices licensed from UCSF</p>



*Active Development Project in 2023 internally or through partnerships

New Global Showcase Site

ClearPoint Global Training & Innovation Center – Solana Beach, CA

- Simulated training experience for surgeons and staff to perform mock procedures and provide development pipeline feedback
- Showcase new technologies to Pharmaceutical and BCI partners
- Home for Clinical Specialists to support cases remotely without travel



New Manufacturing Facility – Transition Complete

~20,000 Sq. Ft. Manufacturing Capability – Carlsbad, CA

- 2,500 Sq. Ft. Clean Room
- Designed for best-in-class lean manufacturing, warehouse and shipping expertise
- Will be available for Neurosurgeon and Pharmaceutical site visits in late 2023



4 Pillar Growth Strategy by 2025

Target Indications of > 1,000,000 Patients Diagnosed Each Year
Potential Total Addressable Market for CLPT of \$12B+



ACHIEVE GLOBAL SCALE

- Expand Global Footprint to 100 Centers
- Achieve Product Clearance Beyond US, EU
- Open New ~20,000 sq ft Manufacturing Facility
- Launch Orchestra and Robotic Platforms

4

NEW THERAPY DEVICES

- Full Market Release for PRISM Neuro Laser
- Integrate Maestro Tools Into Navigation Software
- Launch Array Trajectory Software into Oncology Market
- Penetrate 'Access' Markets to Improve Efficiency (Drill)

3

NEURO NAVIGATION FOR DBS & BCI

- Expand into the Operating Room, Including MER Accessories
- Educate Patients on DBS Options including 'Asleep' and 'Awake' Procedures
- Participate in Trials for new DBS indications
- Launch Pre-Planning and Surgical Navigation Solution for Brain-Computer Interfaces (BCI)

2

BIOLOGICS & DRUG DELIVERY

- Continue to Expand Translational, Pre-Clinical & Clinical Services
- Accumulate Additional Global Partners Across Diverse Indications
- Execute on Development Pipeline for Intracranial Cell Therapy and Spinal Routes of Administration
- Progress Partner Programs Through Regulatory Pathways to Achieve Combination Product Clearances
- Expand Partnership Models to Include Pass Through, Milestone & Royalty Based Collaborative Agreements

1

2023

2025

Executive Summary



Unique platform technology

enabling Precision MRI-Guided Therapies to restore quality of life for some of the most debilitating disorders



Pipeline of new revenue streams

from product improvements, biologic and drug delivery partnerships and services, standalone therapy products, and Brain Computer Interface Navigation



Expandable Platform

with realizable synergies beyond the MRI and into the operating room and radiology suite



Large, growing installed base

in 65+ of 500+ leading Neurosurgery and research centers worldwide



Total potential addressable market

> \$12B for our products, pipeline and partnerships



A growing and passionate team

of embedded scientists and specialists





CLEARPOINT®
NEURO



